- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: HB12  | inebilizumab-cdon | MEDI 551 | MEDI-551 | MEDI551 | Uplizna®
inebilizumab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Inebilizumab is a humanized monoclonal antibody (mAb) directed against CD19, a cell-surface antigen expressed on cells of B cell lineage. Inebilizumab has potential immunomodulating and antineoplastic activities. Tested preclinically as a mouse anti-CD19 mAb (clone HB12; ), and initially humanized by Cellective Therapeutics, Inc. (a spinout company from Duke University where the antibody began its life) prior to being acquired by MedImmune (now part of Astra Zeneca) for commercial development.
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. A protein BLAST search of patented sequences reveals 100% matches between the heavy and light variable sequences of inebilizumab and sequences 106 and 111 respectively, in patent US8323653 B2 . A detailed peptide sequence analysis suggests that inebilizumab is likely to be clone 16C4 in this patent.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Inebilizumab exhibits ADCC in vitro and in vivo , and mediates in vitro ADCC and antibody-dependent cellular phagocytosis (ADCP) activities of primary human natural killer (NK) cells and macrophages against precursor-B acute lymphoblastic leukemia (ALL) cell lines and pediatric patient blasts . These effects of inebilizumab are also described in patent US8323653 B2 . The data in the table below is the preferred affinity quoted in the patent as no precise affinity constant is provided for 16C4 binding to CD19.|
|Selectivity at other protein targets|
|Key to terms and symbols||Click column headers to sort|